Keros Therapeutics (NASDAQ:KROS) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a strong sell rating in a report issued on Sunday morning.

Several other equities analysts also recently issued reports on KROS. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Leerink Partners dropped their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Hold” and a consensus target price of $20.50.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $10.61 on Friday. The stock has a market cap of $210.40 million, a PE ratio of -2.87 and a beta of 0.99. The business has a fifty day moving average of $10.65 and a two-hundred day moving average of $11.95. Keros Therapeutics has a 52-week low of $9.69 and a 52-week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Analysts predict that Keros Therapeutics will post -5.16 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Nima Farzan sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the sale, the director owned 9,767 shares of the company’s stock, valued at $104,799.91. This represents a 21.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at $104,702.24. The trade was a 21.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,425 shares of company stock valued at $89,994 over the last ninety days. 12.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of large investors have recently modified their holdings of KROS. The Manufacturers Life Insurance Company boosted its stake in Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after acquiring an additional 988 shares during the last quarter. UBS Group AG grew its holdings in Keros Therapeutics by 1.1% during the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock valued at $1,643,000 after purchasing an additional 1,091 shares during the period. Strs Ohio increased its stake in Keros Therapeutics by 3.9% in the fourth quarter. Strs Ohio now owns 29,300 shares of the company’s stock valued at $597,000 after purchasing an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. acquired a new stake in Keros Therapeutics in the fourth quarter worth $29,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.